Showing results (11-20 of 23) with videos related to
Sort By:
Pageof 3
Cardio-Oncology (London, England)|January 15, 2024
Soluble urokinase plasminogen activator receptor and cardiotoxicity in doxorubicin-treated breast cancer patients: a prospective exploratory studyJian Chu, Lillian Tung, Issam Atallah, et al.Cancer Chemotherapy and Pharmacology|June 19, 2014
Population pharmacokinetics of trastuzumab emtansine (T-DM1), a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implications of the effect of covariatesDan Lu, Sandhya Girish, Yuying Gao, et al.JAMA|October 20, 2005
Genetic testing in an ethnically diverse cohort of high-risk women: a comparative analysis of BRCA1 and BRCA2 mutations in American families of European and African ancestryRita Nanda, L Philip Schumm, Shelly Cummings, et al.The Breast Journal|October 23, 2002
Predictors of lymph node metastasis in T1 breast carcinoma, stratified by patient ageAmila Orucevic, Vijaya B Reddy, Kenneth J Bloom, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 20, 2006
Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancerNicholas Robert, Brian Leyland-Jones, Lina Asmar, et al.Cancer Reports (Hoboken, N.J.)|September 4, 2020
Paired tumor sequencing and germline testing in breast cancer management: An experience of a single academic centerElizabeth Elliott, Virginia Speare, James Coggan, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 30, 2018
Central Nervous System Metastasis in Patients with HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from SystHERsSara A Hurvitz, Joyce O'Shaughnessy, Ginny Mason, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 28, 2019
Baseline Characteristics, Treatment Patterns, and Outcomes in Patients with HER2-Positive Metastatic Breast Cancer by Hormone Receptor Status from SystHERsMelody Cobleigh, Denise A Yardley, Adam M Brufsky, et al.The Oncologist|February 12, 2020
De Novo Versus Recurrent HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs RegistryDebu Tripathy, Adam Brufsky, Melody Cobleigh, et al.Breast Cancer Research and Treatment|February 28, 2021
Baseline characteristics and first-line treatment patterns in patients with HER2-positive metastatic breast cancer in the SystHERs registryPeter A Kaufman, Sara A Hurvitz, Joyce O'Shaughnessy, et al.Pageof 3